Medtronic Launches Novel Clinical Trial Evaluating Spinal Cord Stimulation Therapy for Heart Failure

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the global launch of the Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial. It is the industrys first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation (SCS), or neurostimulation, to improve clinical ...